Back
News Non classé
1 min read

[Press Release] XAV-19, the anti-SARS-CoV-2 GH-pAb of XENOTHERA best-in-class against all variants including BQ. 1.1

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 21 avril 2023

Related Posts

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

Read More

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

Read More

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in